Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen.

ABSTRACT: There are no effective treatment options for most patients with metastatic colorectal cancer (mCRC). mCRC remains a leading cause of tumor-related death, with a five-year survival rate of only 15%, highlighting the urgent need for novel pharmacological products. Current standard drugs are based on cytotoxic chemotherapy, VEGF inhibitors, EGFR antibodies, and multikinase inhibitors. The antibody-based delivery of pro-inflammatory cytokines provides a promising and differentiated strategy to improve the treatment outcome for mCRC patients. Here, we describe the generation of a novel fully human monoclonal antibody (termed F4) targeting the carcinoembryonic antigen (CEA), a tumor-associated antigen overexpressed in colorectal cancer and other malignancies. The F4 antibody was selected by anti

SUBMITTER: Pluss L 

PROVIDER: S-EPMC10228411 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature